DE60221674T2 - Lyophilisierte formulierung enthaltend olanzapin - Google Patents

Lyophilisierte formulierung enthaltend olanzapin Download PDF

Info

Publication number
DE60221674T2
DE60221674T2 DE60221674T DE60221674T DE60221674T2 DE 60221674 T2 DE60221674 T2 DE 60221674T2 DE 60221674 T DE60221674 T DE 60221674T DE 60221674 T DE60221674 T DE 60221674T DE 60221674 T2 DE60221674 T2 DE 60221674T2
Authority
DE
Germany
Prior art keywords
olanzapine
disorders
formulation according
formulation
dsm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60221674T
Other languages
German (de)
English (en)
Other versions
DE60221674D1 (de
Inventor
Kurt Douglas Franklin DEKEMPER
Alan Lee Martinsville FITES
Steven L. West Lafayette NAIL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE60221674D1 publication Critical patent/DE60221674D1/de
Publication of DE60221674T2 publication Critical patent/DE60221674T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE60221674T 2001-07-20 2002-07-05 Lyophilisierte formulierung enthaltend olanzapin Expired - Lifetime DE60221674T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30682901P 2001-07-20 2001-07-20
US306829P 2001-07-20
US38647402P 2002-06-07 2002-06-07
US386474P 2002-06-07
PCT/US2002/019799 WO2003007912A2 (en) 2001-07-20 2002-07-05 Lyophilized formulation comprising olanzapine

Publications (2)

Publication Number Publication Date
DE60221674D1 DE60221674D1 (de) 2007-09-20
DE60221674T2 true DE60221674T2 (de) 2008-04-30

Family

ID=26975390

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60221674T Expired - Lifetime DE60221674T2 (de) 2001-07-20 2002-07-05 Lyophilisierte formulierung enthaltend olanzapin

Country Status (32)

Country Link
US (1) US20040176357A1 (enExample)
EP (1) EP1423124B1 (enExample)
JP (1) JP2004537546A (enExample)
KR (1) KR20040017330A (enExample)
CN (1) CN1537007A (enExample)
AR (1) AR036180A1 (enExample)
AT (1) ATE369137T1 (enExample)
AU (1) AU2002320134B2 (enExample)
BR (1) BR0211250A (enExample)
CA (1) CA2448724A1 (enExample)
CO (1) CO5540279A2 (enExample)
CY (1) CY1107759T1 (enExample)
CZ (1) CZ200484A3 (enExample)
DE (1) DE60221674T2 (enExample)
DK (1) DK1423124T3 (enExample)
EA (1) EA006506B1 (enExample)
ES (1) ES2289126T3 (enExample)
HR (1) HRP20040037A2 (enExample)
HU (1) HUP0401157A3 (enExample)
IL (1) IL159098A0 (enExample)
MX (1) MXPA04000541A (enExample)
MY (1) MY135452A (enExample)
NZ (1) NZ529667A (enExample)
PE (1) PE20030281A1 (enExample)
PL (1) PL366614A1 (enExample)
PT (1) PT1423124E (enExample)
SI (1) SI1423124T1 (enExample)
SK (1) SK182004A3 (enExample)
SV (1) SV2003001179A (enExample)
UA (1) UA80095C2 (enExample)
WO (1) WO2003007912A2 (enExample)
ZA (1) ZA200400798B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323459B2 (en) * 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
WO2006076124A2 (en) * 2004-12-16 2006-07-20 Nektar Therapeutics Stable, non-crystalline formulation comprising olanzapine
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
EP3735223A4 (en) * 2018-01-05 2021-10-13 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
PE20212195A1 (es) * 2019-03-01 2021-11-15 Eurofarma Laboratorios S A Composicion farmaceutica liofilizada de antiinflamatorio no esteroideo
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115006406A (zh) * 2021-12-28 2022-09-06 南京清普生物科技有限公司 一种稳定的奥氮平制剂
WO2025056094A1 (zh) * 2023-09-15 2025-03-20 广州帝奇医药技术有限公司 一种冻干制剂和注射液及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0421297T3 (da) * 1989-09-30 1994-01-17 Eisai Co Ltd Injicerbare præparater indeholdende cephalosporin som lægemiddel og anvendelse deraf
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
UA80095C2 (en) 2007-08-27
WO2003007912A3 (en) 2003-05-01
CA2448724A1 (en) 2003-01-30
PE20030281A1 (es) 2003-03-27
CY1107759T1 (el) 2013-06-19
PL366614A1 (en) 2005-02-07
CZ200484A3 (cs) 2005-01-12
CN1537007A (zh) 2004-10-13
ATE369137T1 (de) 2007-08-15
EP1423124B1 (en) 2007-08-08
EA200400211A1 (ru) 2004-06-24
WO2003007912A2 (en) 2003-01-30
JP2004537546A (ja) 2004-12-16
DE60221674D1 (de) 2007-09-20
ES2289126T3 (es) 2008-02-01
HRP20040037A2 (en) 2004-06-30
AR036180A1 (es) 2004-08-18
EA006506B1 (ru) 2005-12-29
NZ529667A (en) 2006-02-24
IL159098A0 (en) 2004-05-12
HUP0401157A3 (en) 2008-01-28
CO5540279A2 (es) 2005-07-29
US20040176357A1 (en) 2004-09-09
SI1423124T1 (sl) 2008-02-29
MY135452A (en) 2008-04-30
SV2003001179A (es) 2003-07-29
AU2002320134B2 (en) 2007-04-05
KR20040017330A (ko) 2004-02-26
BR0211250A (pt) 2004-07-27
EP1423124A2 (en) 2004-06-02
HUP0401157A2 (hu) 2004-10-28
PT1423124E (pt) 2007-10-29
DK1423124T3 (da) 2007-12-03
MXPA04000541A (es) 2004-05-04
SK182004A3 (en) 2004-09-08
ZA200400798B (en) 2005-07-27
HK1066484A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
DE69317578T2 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE69400435T2 (de) Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson-syndromen
DE69401577T2 (de) Verabreichung von lamotrigin zur behandlung von neuro-aids
DE3590035T1 (de) Diphenhydramin enthaltende, analgetische und anti-inflammatorische Mittel und Verfahren zu ihrer Verwendung
DE10361259A1 (de) Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE60110185T2 (de) Zusammensetzung und Verfahren zur parenteralen Anwendung von Ibuprofen-D,L-, oder L-Lysinat
EP1423124B1 (en) Lyophilized formulation comprising olanzapine
EP3849976B1 (en) A gaba a receptor ligand
AU2002320134A1 (en) Lyophilized formulation comprising olanzapine
EP1750700A1 (de) Flüssige zubereitung für die veterinärmedizin; verfahren zu deren herstellung und deren verwendung
DE69516110T2 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
DE202007019385U1 (de) Pharmazeutische Zusammensetzungen, umfassend Clopidogrel
DE69127285T2 (de) Verwendung von verbindungen zur behandlung von altersbedingtem gedächtnisschwund und anderen kognitiven störungen
DE60114567T2 (de) Selektive acylierung von a82846-glycopeptid-analoge
DE69516075T2 (de) Verwendung von einem azabicyclischen Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen
DE60122384T2 (de) Verfahren zur herstellung einer beständige pharmazeutische form von paclitaxel
DE68912947T2 (de) Ein lösliches ibopamin-salz enthaltende augenarzneizubereitung.
DE68905995T2 (de) Parenteral anzuwendende 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1h-imidazol-4-yl)-methyl)-piperazin enthaltende zubereitungen.
DE69426317T2 (de) Verwendung von Beta-Naphthochinonderivaten zur Hemmung von Blutplättchen-Aggregation
DE3789173T2 (de) Verwendung von Ketamin zur Herstellung von Arzneimitteln zur Prävention oder Linderung der Effekte von Schlaganfall bei einer Person mit erhöhtem Risiko für Schlaganfall.
HK1066484B (en) Lyophilized formulation comprising olanzapine
EA002676B1 (ru) Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка
DE69804034T2 (de) Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion
DE2265631C2 (de) Arzneimittel zur Behandlung psychischer Erkrankungen
DE2916880A1 (de) Arzneimittel mit sedativer und schlafinduzierender wirkung sowie dieses enthaltende pharmazeutische zubereitungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN